antibody

HRP-conjugated Goat Anti-Human Apolipoprotein B-100

MBS390016

0.5 mL

275 USD

polyclonal

goat

HRP

western blot, ELISA, enzyme immunoassay

Antibody

HRP-conjugated Goat Anti-Human Apolipoprotein B-100

Apolipoprotein B-100

Horseradish Peroxidase (HRP) conjugated Goat Anti-Human Apolipoprotein B-100/48 (Apo B-100/48), Polyclonal Antibody

apolipoprotein B-100; Apolipoprotein B-100; apolipoprotein B-100; apoB-48; apoB-100; apo B-100; mutant Apo B 100; apolipoprotein B48; apolipoprotein B (including Ag(x) antigen); apolipoprotein B

APOB; APOB; FLDB; LDLCQ4; Apo B-100; Apo B-48

APOB_HUMAN

Goat

4563

Specifically binds to human apo B-48/100. Dilution for immunoblot and ELISA range: 200 to 8,000.

1 ml in Freeze-dried powder.

1 mg / ml

Freeze-dried product should be stored refrigerated until opened. After opening, restore to 0.5 ml with distilled water. If it is not completely clear after standing for 1-2 Hours at room temperature, centrifuge the product. It is stable for several weeks at 4 degree C as an undiluted liquid. Do not use for more than one day after dilution. For extended storage after reconstitution, we suggest aliquot to avoid repeated freezing and thawing; or the addition of an equal volume of glycerol to make a final glycerol concentration of 50%, followed by storage at -20 degree C. The concentration of protein and buffer salts will decrease to one-half of the original after the addition of glycerol

ELISA (EIA), Immunoblot (IB)

Freeze-dried powder. Dilution for Immunoblot & ELISA range: 1,000 to 8,000. Use: The antibody can be used for detection of human apo B-48/100 in plasma and lipoproteins, immunoassays and immunoblots.

Source Note: Polyclonal antibody purified by human apolipoprotein B-100- Sepharose affinity column, and conjugated with HRP.

Preservative: 50 mM PBS, 0.1 M NaCl, pH 7.4 and 0.01% Thimersol. Stabilizer: 10 mg / ml Bovine Serum Albumin.

HRP Antibodies

105990532

NP_000375.2

NM_000384.2

P04114

515,605 Da

Binding And Uptake Of Ligands By Scavenger Receptors Pathway (771599); Cell Surface Interactions At The Vascular Wall Pathway (106062); Chylomicron-mediated Lipid Transport Pathway (106157); Disease Pathway (530764); Diseases Associated With Visual Transduction Pathway (771581); FOXA1 Transcription Factor Network Pathway (137979); Fat Digestion And Absorption Pathway (194385); Fat Digestion And Absorption Pathway (194324); Hemostasis Pathway (106028); LDL-mediated Lipid Transport Pathway (106159)

This gene product is the main apolipoprotein of chylomicrons and low density lipoproteins. It occurs in plasma as two main isoforms, apoB-48 and apoB-100: the former is synthesized exclusively in the gut and the latter in the liver. The intestinal and the hepatic forms of apoB are encoded by a single gene from a single, very long mRNA. The two isoforms share a common N-terminal sequence. The shorter apoB-48 protein is produced after RNA editing of the apoB-100 transcript at residue 2180 (CAA- UAA), resulting in the creation of a stop codon, and early translation termination. Mutations in this gene or its regulatory region cause hypobetalipoproteinemia, normotriglyceridemic hypobetalipoproteinemia, and hypercholesterolemia due to ligand-defective apoB, diseases affecting plasma cholesterol and apoB levels. [provided by RefSeq, Jul 2008]

Function: Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor. Subunit structure: Interacts with PCSK9. Ref.38. Subcellular location: Cytoplasm. Secreted Ref.38. Induction: Up-regulated in response to enterovirus 71 (EV71) infection (at protein level). Ref.34. Post-translational modification: Palmitoylated; structural requirement for proper assembly of the hydrophobic core of the lipoprotein particle. Ref.31. Involvement in disease: Familial hypobetalipoproteinemia 1 (FHBL1) [MIM:107730]: A disorder of lipid metabolism characterized by less than 5th percentile age- and sex-specific levels of low density lipoproteins, and dietary fat malabsorption. Clinical presentation may vary from no symptoms to severe gastrointestinal and neurological dysfunction similar to abetalipoproteinemia.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.46Familial ligand-defective apolipoprotein B-100 (FDB) [MIM:144010]: Dominantly inherited disorder of lipoprotein metabolism leading to hypercholesterolemia and increased proneness to coronary artery disease (CAD). The plasma cholesterol levels are dramatically elevated due to impaired clearance of LDL particles by defective APOB/E receptors.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.40 Ref.42 Ref.44 Ref.49Defects in APOB associated with defects in other genes (polygenic) can contribute to hypocholesterolemia. Sequence similarities: Contains 1 vitellogenin domain. RNA editing: Edited at position 2180.The stop codon (UAA) at position 2180 is created by RNA editing. Apo B-48, derived from the fully edited RNA, is produced only in the intestine and is found in chylomicrons. Apo B-48 is a shortened form of apo B-100 which lacks the LDL-receptor region. The unedited version (apo B-100) is produced by the liver and is found in the VLDL and LDL. Sequence caution: The sequence AAA51752.1 differs from that shown. Reason: Frameshift at positions 942, 951, 1139, 1165, 1164, 1371 and 1385.

0.5 mL

275 USD

1 mL

400